These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 16473763

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis.
    Yamaoka-Tojo M, Tojo T, Kim HW, Hilenski L, Patrushev NA, Zhang L, Fukai T, Ushio-Fukai M.
    Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):1991-7. PubMed ID: 16763158
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Endothelial cadherins and tumor angiogenesis.
    Cavallaro U, Liebner S, Dejana E.
    Exp Cell Res; 2006 Mar 10; 312(5):659-67. PubMed ID: 16256984
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells.
    Deleuze V, Chalhoub E, El-Hajj R, Dohet C, Le Clech M, Couraud PO, Huber P, Mathieu D.
    Mol Cell Biol; 2007 Apr 10; 27(7):2687-97. PubMed ID: 17242194
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells.
    Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T, Cinieri S, Veronesi G, Pruneri G, Lampertico P, Iavarone M, Martinelli G, Goldhirsch A, Bertolini F.
    Cancer Res; 2004 Jun 15; 64(12):4373-7. PubMed ID: 15205354
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. VE-cadherin status as an indicator of microvascular permeability.
    Monaghan-Benson E, Burridge K.
    Methods Mol Biol; 2013 Jun 15; 1046():335-42. PubMed ID: 23868598
    [Abstract] [Full Text] [Related]

  • 15. Endothelial barrier stabilization by a cyclic tandem peptide targeting VE-cadherin transinteraction in vitro and in vivo.
    Heupel WM, Efthymiadis A, Schlegel N, Müller T, Baumer Y, Baumgartner W, Drenckhahn D, Waschke J.
    J Cell Sci; 2009 May 15; 122(Pt 10):1616-25. PubMed ID: 19420236
    [Abstract] [Full Text] [Related]

  • 16. [VE-cadherin takes a walk on the wild side].
    Gavard J, Gutkind JS.
    Med Sci (Paris); 2007 Feb 15; 23(2):119-21. PubMed ID: 17291415
    [No Abstract] [Full Text] [Related]

  • 17. Glucocorticoids increase VE-cadherin expression and cause cytoskeletal rearrangements in murine brain endothelial cEND cells.
    Blecharz KG, Drenckhahn D, Förster CY.
    J Cereb Blood Flow Metab; 2008 Jun 15; 28(6):1139-49. PubMed ID: 18231113
    [Abstract] [Full Text] [Related]

  • 18. Breaking the VE-cadherin bonds.
    Gavard J.
    FEBS Lett; 2009 Jan 05; 583(1):1-6. PubMed ID: 19059243
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites.
    Le Bras A, Lionneton F, Mattot V, Lelièvre E, Caetano B, Spruyt N, Soncin F.
    Oncogene; 2007 Nov 22; 26(53):7480-9. PubMed ID: 17563748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.